Opus Genetics Inc. (IRD)
1.10
-0.05 (-4.35%)
At close: Mar 25, 2025, 3:59 PM
1.07
-2.38%
After-hours: Mar 25, 2025, 07:56 PM EDT
-4.35% (1D)
| Bid | 1 |
| Market Cap | 34.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | -1.01 |
| Forward PE | -1.38 |
| Analyst | Buy |
| Ask | 1.15 |
| Volume | 854,462 |
| Avg. Volume (20D) | 209,093 |
| Open | 1.15 |
| Previous Close | 1.15 |
| Day's Range | 0.96 - 1.16 |
| 52-Week Range | 0.81 - 2.34 |
| Beta | 0.26 |
About IRD
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a smal...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 19, 2015
Employees 14
Stock Exchange NASDAQ
Ticker Symbol IRD
Website https://opusgtx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for IRD stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 627.21% from the latest price.
Stock Forecasts3 months ago
+18.93%
Opus Genetics shares are trading higher after the ...
Unlock content with
Pro Subscription
